HER2-Low Breast Cancer
common.study.values.description
“Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]”
This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before. Participants' cancer: - Cannot be removed by an operation - Has spread to other parts of the body
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Trastuzumab deruxtecan (DS-8201a)
DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously
Drug - Capecitabine
Administered according to label, as one option for Physician's Choice (determined before randomization)
Drug - Eribulin
Administered according to label, as one option for Physician's Choice (determined before randomization)
Drug - Gemcitabine
Administered according to label, as one option for Physician's Choice (determined before randomization)
Drug - Paclitaxel
Administered according to label, as one option for Physician's Choice (determined before randomization)
Drug - Nab-paclitaxel
Administered according to label, as one option for Physician's Choice (determined before randomization)
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
common.study.values.clinical-trial-id
NCT03734029
participant.views.study.view.id
en5Yld
